Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2013, with the report issued on April 26, 2013. The filing primarily announces a regulatory milestone in GSK's respiratory development portfolio rather than providing financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report of a specific corporate event and does not contain financial statements.
Material Changes and Corporate Developments
- Regulatory Submission: GSK submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for umeclidinium bromide (UMEC) monotherapy (55 mcg delivered dose).
- Indication: The drug is intended as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
- Product Details: UMEC is an investigational long-acting muscarinic antagonist (LAMA) administered via the ELLIPTA inhaler.
- Future Filings: Regulatory filings for UMEC monotherapy are imminent in the US and planned in other countries during 2013.
Outlook, Risks, and Pipeline Context
UMEC monotherapy is part of a broader late-stage respiratory portfolio. Other assets mentioned include:
- Umeclidinium/vilanterol (UMEC/VI, proposed brand name ANORO).
- Fluticasone furoate/vilanterol (FF/VI, proposed brand names RELVAR and BREO).
- Vilanterol (VI) monotherapy.
- MABA (GSK961081), developed in collaboration with Theravance.
- Investigational medicines FF monotherapy and anti-IL5 MAb (mepolizumab).
Forward-Looking Statement: GSK cautions that actual results may differ materially from projections due to risks and uncertainties, referencing Item 3.D "Risk factors" in the 2012 Annual Report on Form 20-F.
Key Facts for Investor Verification
- Verify the status of the EMA review process for the UMEC monotherapy MAA.
- Confirm the timeline for the imminent US regulatory filing for UMEC.
- Review the 2012 Form 20-F for detailed risk factors affecting the respiratory pipeline.
- Note that all mentioned investigational medicines (including ANORO, RELVAR, and BREO) are not currently approved by any regulatory authority.